DGTR Terminates Anti-Dumping Investigation on MEG Imports Impacting Pharma Packaging

However, in its final findings dated October 27, 2022, the DGTR concluded that the domestic industry had not suffered material injury due to the imports in question. This finding was contested by Reliance Industries, which appealed to the Customs, Excise & Service Tax Appellate Tribunal (CESTAT). The tribunal directed the DGTR to reexamine the case, specifically addressing concerns about the selective examination of injury trends, leading to the remand of the matter back to the authority.

Also Read: India begins anti-dumping investigation into import of vitamin from China, EU

In September 2024, the domestic industry, Reliance Industries Limited requested the termination of the investigation, citing that the data from the period under investigation was now outdated, and no longer reflected the current market conditions. In compliance with Rule 14(a) of the Anti-Dumping Rules, which mandates the termination of investigations if the domestic industry requests it in writing, the DGTR has officially ended the investigation. It noted;

"In view of the request made by the domestic industry and under the provisions of Rule 14(a) of the Rules, the Authority hereby terminates the investigation initiated on June 28, 2021."

Mono Ethylene Glycol (MEG) is a key raw material used in the production of polyethylene terephthalate (PET) resins. PET, a durable, transparent, and lightweight plastic from the polyester family, is widely used in manufacturing plastic bottles for pharmaceutical packaging. As a result, ensuring the quality of PET is of significant importance in the pharmaceutical industry.